Researchers at Alligator Bioscience AB and Lund University have developed a bispecific therapeutic antibody, ATOR-4066, that simultaneously targets the immune cell receptor CD40 and the tumor antigen CEACAM5.
Athernal Bio Ltd. has launched, supported by £3.5 million (US$4.7 million) in funding and with a focus on the development of targeted immunotherapies for early intervention in high-risk clonal hematopoiesis, a cancer precursor condition which can lead to acute myeloid leukemia (AML) and other hematological cancers.
Full-Life Technologies Ltd. announced Sept. 29 the completion of a $77 million financing, comprising $50 million in series C equity and $27 million in debt financing, which will be used to advance a portfolio of radiopharmaceuticals and radionuclide-drug conjugates worldwide.
Contineum Therapeutics Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, renal fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and scleroderma.
Zai Lab (Shanghai) Co. Ltd. and Zai Lab (US) LLC have divulged spirocyclic compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Forx Therapeutics AG has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Ovarian cancer remains unresponsive to immune checkpoint inhibitors due to its ability to suppress cytotoxicity from immune cells that are infiltrating the tumor, where the O-glycosylation pathway may be disrupted. Precision Biologics Inc. is developing PB-vcMMAE-5, an antibody-drug conjugate composed of the monoclonal antibody PB-223, which targets tumor-specific truncated core-2 O-glycans, conjugated to microtubule inhibitor MMAE and with a drug-to-antibody ratio of 3.92.
Generating gametes from nonreproductive tissues could help overcome infertility. Previous studies have successfully transformed stem cells into viable oocytes through cellular reprogramming. Scientists at Oregon Health & Science University (OHSU) developed a method to derive them from skin cells via somatic cell nuclear transfer (SCNT), unlocking a mechanism that blends mitosis and meiosis. Now, the researchers have taken another step forward by generating fertilizable eggs from human skin cells.
Palmetto GBA, the Medicare administrative contractor for most of the southeastern U.S., has opened a coverage analysis for the use of irreversible electroporation for a variety of cancers, but Palmetto has made it clear that it is unwilling to cover the procedure pending additional evidence.
RSS
